These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36919687)

  • 21. Evaluation of study discontinuations with tapentadol inmmediate release and oxycodone immediate release in patients with low back or osteoarthritis pain.
    Vorsanger G; Xiang J; Okamoto A; Upmalis D; Moskovitz B
    J Opioid Manag; 2010; 6(3):169-79. PubMed ID: 20642246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tapentadol shows lower intrinsic efficacy at µ receptor than morphine and oxycodone.
    Manandhar P; Connor M; Santiago M
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00921. PubMed ID: 35084120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tapentadol is effective in the management of moderate-to-severe cancer-related pain in opioid-naïve and opioid-tolerant patients: a retrospective study.
    Sazuka S; Koitabashi T
    J Anesth; 2020 Dec; 34(6):834-840. PubMed ID: 32648017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxycodone for cancer-related pain.
    Schmidt-Hansen M; Bennett MI; Arnold S; Bromham N; Hilgart JS
    Cochrane Database Syst Rev; 2015 Feb; (2):CD003870. PubMed ID: 25723351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tapentadol: A Review of Experimental Pharmacology Studies, Clinical Trials, and Recent Findings.
    Alshehri FS
    Drug Des Devel Ther; 2023; 17():851-861. PubMed ID: 36974332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain.
    Daniels S; Casson E; Stegmann JU; Oh C; Okamoto A; Rauschkolb C; Upmalis D
    Curr Med Res Opin; 2009 Jun; 25(6):1551-61. PubMed ID: 19445652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bowel function after tapentadol and oxycodone immediate release (IR) treatment in patients with low back or osteoarthritis pain.
    Kwong WJ; Hammond G; Upmalis D; Okamoto A; Yang M; Kavanagh S
    Clin J Pain; 2013 Aug; 29(8):664-72. PubMed ID: 23835764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tapentadol immediate release for moderate to severe acute post-surgery pain.
    Viscusi ER; Allard R; Sohns M; Eerdekens M
    J Opioid Manag; 2019; 15(1):51-67. PubMed ID: 30855723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial.
    Schwartz S; Etropolski M; Shapiro DY; Okamoto A; Lange R; Haeussler J; Rauschkolb C
    Curr Med Res Opin; 2011 Jan; 27(1):151-62. PubMed ID: 21162697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study.
    Cepeda MS; Fife D; Ma Q; Ryan PB
    J Pain; 2013 Oct; 14(10):1227-41. PubMed ID: 23850177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective, multicenter, open-label study of the clinical efficacy of tapentadol extended-release in the treatment of cancer-related pain and improvement in the quality of life of opioid-naïve or opioid-resistant patients.
    Jung JY; Chon HJ; Choi YJ; Yeon SE; Choi SY; Lee KH
    Support Care Cancer; 2022 Jul; 30(7):6103-6112. PubMed ID: 35420330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of tapentadol as a strong opioid in cancer pain management: a systematic and critical review.
    Mercadante S
    Curr Med Res Opin; 2017 Nov; 33(11):1965-1969. PubMed ID: 28906155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study.
    Kleinert R; Lange C; Steup A; Black P; Goldberg J; Desjardins P
    Anesth Analg; 2008 Dec; 107(6):2048-55. PubMed ID: 19020157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New Opioid Options in Japan - Methadone, Tapentadol and Hydromorphone].
    Takagi Y; Aruga E
    Gan To Kagaku Ryoho; 2018 Feb; 45(2):205-211. PubMed ID: 29483406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Tapentadol Immediate Release for Acute Pain: A Systematic Review and Meta-Analysis.
    Wang X; Narayan SW; Penm J; Patanwala AE
    Clin J Pain; 2020 May; 36(5):399-409. PubMed ID: 31990693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Combination Therapy of Oxycodone and Tapentadol Was Effective for Intractable Pain Caused by Breast Cancer Bone Metastasis - A Case Report].
    Matsuura T; Kusakabe A; Kessoku T; Honda Y; Yoshimi A; Goto A; Yoshida H; Sukegawa A; Nakajima A; Ichikawa Y
    Gan To Kagaku Ryoho; 2018 Mar; 45(Suppl 1):74-76. PubMed ID: 29650881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine.
    Ikenberg R; Hertel N; Moore RA; Obradovic M; Baxter G; Conway P; Liedgens H
    J Med Econ; 2012; 15(4):724-36. PubMed ID: 22364286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Sustained-release Opioids: Morphine, Oxycodone and Tapentadol].
    Takahashi Y; Iseki M
    Masui; 2015 Nov; 64(11):1133-40. PubMed ID: 26689063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of tapentadol ER for managing moderate to severe chronic pain.
    Afilalo M; Morlion B
    Pain Physician; 2013 Jan; 16(1):27-40. PubMed ID: 23340531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor.
    Hartrick CT; Rozek RJ
    CNS Drugs; 2011 May; 25(5):359-70. PubMed ID: 21476608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.